Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...

Pharma giant AbbVie reveals plans to expand its presence in the obesity drug market through pipeline development and ...

By Christy Santhosh Jan 14 (Reuters) - AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...